HIV Infections Clinical Trial
Official title:
Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment (HAART) on Immune Functions Relevant for MAC and Other Opportunistic Infections
NCT number | NCT00000895 |
Other study ID # | ACTG 341 |
Secondary ID | 11312 |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Est. completion date | August 2001 |
Verified date | October 2021 |
Source | National Institute of Allergy and Infectious Diseases (NIAID) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood. This study also evaluates the relationships between the amount of HIV in the blood, immune system functions, and the presence of MAC infection. HIV-positive patients are at risk for MAC infection because their immune systems have been weakened by HIV. It is hoped that aggressive treatment with anti-HIV drugs may improve their immune systems enough to prevent against MAC.
Status | Completed |
Enrollment | 85 |
Est. completion date | August 2001 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria You may be eligible for this study if you: - Are HIV-positive. - Have a CD4 count under 50 cells/mm3 or between 100 and 250 cells/mm3 within 30 days of study entry. - Have at least one symptom (e.g., fever, diarrhea, or weight loss) suggestive of MAC infection. - Have MAC infection with 7 days or less of MAC treatment. - Have an HIV blood level greater than 10,000 copies/ml within 30 days of study entry. - Are 18 years of age or older. Exclusion Criteria You will not be eligible for this study if you: - Have any active infection (except for MAC in Group 2 patients) or any cancer. - Are unable to follow an acceptable anti-HIV drug regimen (Groups 2 and 3). - Are pregnant or breast-feeding. |
Country | Name | City | State |
---|---|---|---|
United States | Emory Univ | Atlanta | Georgia |
United States | Univ of Alabama at Birmingham | Birmingham | Alabama |
United States | SUNY / Erie County Med Ctr at Buffalo | Buffalo | New York |
United States | Cook County Hosp | Chicago | Illinois |
United States | Northwestern Univ Med School | Chicago | Illinois |
United States | Rush Presbyterian - Saint Luke's Med Ctr | Chicago | Illinois |
United States | Univ of Cincinnati | Cincinnati | Ohio |
United States | Case Western Reserve Univ | Cleveland | Ohio |
United States | Ohio State Univ Hosp Clinic | Columbus | Ohio |
United States | Univ of Texas Southwestern Med Ctr of Dallas | Dallas | Texas |
United States | Univ of Texas, Southwestern Med Ctr of Dallas | Dallas | Texas |
United States | Univ of Texas Galveston | Galveston | Texas |
United States | Division of Inf Diseases/ Indiana Univ Hosp | Indianapolis | Indiana |
United States | Indiana Univ Hosp | Indianapolis | Indiana |
United States | Univ of Southern California / LA County USC Med Ctr | Los Angeles | California |
United States | Univ of Miami School of Medicine | Miami | Florida |
United States | Bellevue Hosp / New York Univ Med Ctr | New York | New York |
United States | Beth Israel Med Ctr | New York | New York |
United States | St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr | New York | New York |
United States | Univ of Pennsylvania at Philadelphia | Philadelphia | Pennsylvania |
United States | Univ of Rochester Medical Center | Rochester | New York |
United States | Univ of California / San Diego Treatment Ctr | San Diego | California |
United States | Univ of Washington | Seattle | Washington |
United States | Stanford Univ Med Ctr | Stanford | California |
United States | Howard Univ | Washington | District of Columbia |
United States | Julio Arroyo | West Columbia | South Carolina |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
MacGregor RR, Hafner R, Wu JW, Murphy RL, Perlman DC, Bermudez LE, Inderlied CB, Picker LJ, Wallis RS, Andersen JW, Mahon LF, Koletar SL, Peterson DM; ACTG Protocol 341 Team. Clinical, microbiological, and immunological characteristics in HIV-infected sub — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |